Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance

References

• DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles & practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
   Google Scholar
• Kolitz JE, George SL, Dodge JE. Dose escalation studies of Ara-C (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) <60 years: Final induction results of CALGB 9621. Blood 2001;98:461a, abstract.
   Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265–283.
   Google Scholar
• Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931–959.
   PubMed Web of Science ®Google Scholar
• Karp JE. MDR modulation in acute myelogenous leukemia: Is it dead? Leukemia 2001;15:666–667.
   PubMed Web of Science ®Google Scholar
• Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000;14 :467–473 .
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. J Nat Cancer Inst 2000;92(16):1295–1302.
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340–7358.
   PubMed Web of Science ®Google Scholar
• Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: New targets, new agents. Curr Opin Investig Drugs 2002;3:1652–1659.
   PubMedGoogle Scholar
• Christina L, Linn H, Malin B, Kourosh L, Christer P, Staffan E. Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells. Biochem Biophys Res Commun 2004;320:825–832.
   PubMed Web of Science ®Google Scholar
• Baker EK, Osta A El. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003;290:177–194.
   PubMed Web of Science ®Google Scholar
• Scotto KW. Transcriptional regulation of ABC drug transpor-ters. Oncogene 2003;22:7496–7511.
   PubMed Web of Science ®Google Scholar
• Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42: 1007–1017.
   Google Scholar
• Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996; 32A:1070–1081.
   Google Scholar
• List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A southwest oncology group study. Blood 2001;98:3212–3220.
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Versantvoort CH. Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur J Cancer 1996;32A:1002–1009.
   PubMed Web of Science ®Google Scholar
• Misbah Q, Kieran LO, Stacy MF, Nicole AW, William RG, Hans M, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Chin Cancer Res 2005;11:2320–2326.
   Web of Science ®Google Scholar
• Hirrlinger J, Konig J, Keppler D, Lindenau J, Schulz JB, Dringen R. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem 2001;76(2):627–636.
   PubMed Web of Science ®Google Scholar
• Baran Y, Giindaz U, Ural AU. Expression of MDR1 gene in HL60 cells selected with vincristine. Turk J Cancer 2005; 35(2):88–92.
   Google Scholar
• Piskin O, Ozcan MA, Ozsan GH, Ates H, Demirkan F, Alacacioglu I, et al. Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines. Turk J Hematol 2007;24:23–27.
   PubMedGoogle Scholar
• Hirose M. Biology and modulation of multidrug resistance (MDR) in hematological malignancies. Int J Hematol 2002; 76:206–211.
   PubMed Web of Science ®Google Scholar
• Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, et al. MRP and MDR1 gene expression in primary breast carcinomas. Chin Cancer Res 1996;2(7): 1231–1237.
   Web of Science ®Google Scholar
• Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto C, et al. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 2001;276:24901–24910.
   PubMed Web of Science ®Google Scholar
• Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S, et al. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol Res 2006;53:49–61.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, Stein U, et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005;24: 7542–7551.
   Google Scholar
• Baran Y, Gündüz Y, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol 2006;28 (2):163–165.
   PubMedGoogle Scholar
• Dong BX, Chen XQ, Wang Z, Liang R, Bai QX, Huang GS, et al. Difference of gene expression profiles between HL-60/VCR and HL-60 cells detected by human genome genechip. J Exp Hematol Chinese Association of Pathophy-siology 2006;14 (3):492–496.
   Google Scholar
• Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, Darzynkiewicz Z, Blagosklonny MV. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res 2005; 65(10):4401–4407.
   PubMed Web of Science ®Google Scholar
• Pu QQ, Bezwoda WR. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function. Mol Pharm 1999; 56(1):147–153.
   PubMed Web of Science ®Google Scholar
• Higashigawa M, Ido M, Kuwabara H, Hon H, Ohkubo T, Kawasaki H, et al. Membrane transport of 1-²-D-arabinofuranosylcytosine and accumulation of 1-²-D-arabinofuranosyl-cytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine. Leuk Res 1991;15(4):255–262.
   PubMed Web of Science ®Google Scholar
• Lopes EC, Scolnik M, Alvarez E, Hajos SE. Modulator activity of PSC 833 and cyclosporin-a in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells. Leuk Res 2001;25(1):85–93.
   PubMed Web of Science ®Google Scholar
• Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, et al. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 1999;93:4086–4095.
   PubMed Web of Science ®Google Scholar
• Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB, Roepe PD, et al. The multidrug resistance phenotype confers immunological resistance. J Exp Med 1996;183:2699–2704.
   PubMed Web of Science ®Google Scholar
• Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, et al. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother Pharmacol 2004;54:283–289.
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Chin Oncol 2002;20: 4508–4516.
   PubMed Web of Science ®Google Scholar
• Elghetany MT, Lacombe F. Physiologic variations in granulocytic surface antigen expression: Impact of age, gender, pregnancy, race, and stress. J Leukoc Biol 2004;75: 157–162.
   PubMed Web of Science ®Google Scholar